Cancer Family
Nervous System Neoplasm
CI-CAN-00000038Explore in graph →
Non-malignant1,523 active trials9 approved drugs210 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000038Explore in graph →
Clinical trials
5,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05592743 | Vorasidenib Expanded Access Program | approved for marketing | — | — | ServierINDUSTRY | 0 | Jul 24, 2026 | clinicaltrials |
| NCT04617002 | Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas | approved for marketing | — | — | Jazz PharmaceuticalsINDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT05760586 |
| Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma |
| approved for marketing |
| — |
| — |
| Day One Biopharmaceuticals, Inc.INDUSTRY |
| 0 |
| Aug 12, 2024 |
| clinicaltrials |
| NCT01377532 | Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma | approved for marketing | — | — | University of California, San FranciscoOTHER | 1 | May 6, 2020 | clinicaltrials |
| NCT02961491 | Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma | approved for marketing | — | — | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 30, 2019 | clinicaltrials |
| NCT00730444 | Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma | approved for marketing | — | — | GE HealthcareINDUSTRY | 1 | Nov 9, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Jul 24, 2026source: clinicaltrials